Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association
Contract with second IPA serving California expands patient access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO , March 26, 2020 /PRNewswire/ --  Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests
View HTML
Toggle Summary Biocept Reports 2019 Fourth Quarter and Full Year Financial Results
- Fourth quarter revenues reached a record $1.8 million, up 108% over the fourth quarter of 2018 and up 17% over the third quarter of 2019 - Fourth quarter commercial revenues increased 94% over the fourth quarter of 2018 and increased 11% over the third quarter of 2019 - Fourth quarter cost of
View HTML
Toggle Summary Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020
SAN DIEGO , March 18, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
View HTML
Toggle Summary Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations
SAN DIEGO , March 9, 2020 /PRNewswire/ --  Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of clinical data
View HTML
Toggle Summary Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market
SAN DIEGO , March 5, 2020 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
View HTML
Toggle Summary Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market
SAN DIEGO , March 2, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
View HTML
Toggle Summary Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations
SAN DIEGO , Feb. 14, 2020 /PRNewswire/ --  Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J.
View HTML
Toggle Summary Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association
Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO , Feb. 10, 2020 /PRNewswire/ -- Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid
View HTML
Toggle Summary Biocept to Present at the 22nd Annual BIO CEO & Investor Conference
SAN DIEGO , Feb. 4, 2020 /PRNewswire/ -- Biocept, Inc.  (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
Biocept's patented Target Selector™ technology enables new specimen type--cerebrospinal fluid (CSF)--to identify biomarkers that can aid physicians in making treatment decisions SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
View HTML